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terms of choice of treatment strategy for longterm treatment of
gastroesophageal reﬂux disease and the associated costs.
METHODS: This study is a follow-up study to the Nexium One
study and is an open observational study in a general practice
setting with 1206 patients. This study was designed as a natu-
ralistic study to emulate a real-life situation as closely as possi-
ble. The observational period was six-months. Three groups of
patients were included in to this study: 1) patients who partici-
pated in the Nexium One trial and were included by general
practionernes (GPs), who participated in the Nexium One trial;
2) patients who did not participate in the Nexium One trial and
were included by GPs, who participated in the Nexium One trial;
and 3) patients who did not participate in the Nexium One trial
and were included by GPs, who did not participate in the
Nexium One trial. As to whether the randomised Nexium One
study reﬂected real-life in terms of treatment and associated
costs, this was investigated by comparing direct medical costs,
total costs for the following patients: A) all patients from the
Nexium One study and B) group three patients (see above).
RESULTS/CONCLUSIONS: A signiﬁcant difference was found
in total costs between group three and all the patients in the
Nexium One study. However, there was no signiﬁcant difference
in direct medical costs. In other words, the Nexium One study
reﬂects real-life costs as there is no difference in the costs of treat-
ment between all patients in the Nexium One study and the
patients, who did not participate in the Nexium One study and
were included by GPs who did not participate in the Nexium
One study.
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OBJECTIVES: To assess the validity and subject acceptability of
electronic data capture (EDC) versions of Irritable Bowel Syn-
drome Quality of Life(IBS-QOL), EuroQoL(EQ-5D) and Work
Productivity and Activity Impairment (WPAI:IBS) question-
naires. METHODS: Comparability of EDC and paper question-
naires was evaluated in 72 subjects with IBS who completed a
baseline EDC or paper questionnaire, a crossover questionnaire
24 hours later, and a retest of the crossover version at week-one.
The EDC version was presented on a hand-held device. Compa-
rability was assessed using paired t-test statistics, intraclass cor-
relation coefﬁcients (ICC) and tests for internal consistency
(Cronbach’s alpha). RESULTS: No signiﬁcant differences were
found between scores obtained by paper questionnaire and EDC
at the baseline and crossover assessments. ICCs between base-
line and crossover assessments ranged from 0.83 to 0.96 for the
IBS-QOL scores, 0.82 to 0.96 for the WPAI:IBS scores, and 0.77
to 0.82 for the EQ-5D. Internal consistency was comparable for
the two data collection methods for the IBS-QOL overall score
(0.96) and subscales and the EQ-5D Index (0.70 vs. 0.74). Retest
statistics (ICC) were generally comparable between the EDC and
paper versions for all scores, as was the relationship between
scores and levels of IBS symptom severity. Ease of use was com-
parable for the two modes of administration, but more patients
preferred EDC (47.2%) than the paper questionnaire (23.6%).
CONCLUSIONS: EDC versions of the IBS-QOL, EQ-5D, and
WPAI:IBS are comparable to paper questionnaires in terms of
internal consistency, test-retest reliability, and discriminant valid-
ity and have greater patient acceptability.
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The impact of treatment on health related quality of life
(HRQoL) in CHB patients is unclear. OBJECTIVE: The objec-
tive of this study was to compare the changes in HRQoL from
baseline, as measured by changes in health status using the
EuroQoL 5 Dimensions (EQ-5D) questionnaire, in patients
receiving ETV or LAM treatment. Utility scores are anchored
between full health (1) and death (0). METHODS: This was a
randomized double blind, double dummy, active controlled trial.
Questionnaires were administered prior to the physician visit at
baseline, Weeks 24 and 48. Mean changes in health index score
(HIS) and visual analog scale (VAS) score from baseline were cal-
culated in all treated patients. Proportions of patients who had
improvement or no change in health dimensions were compared
between the two treatment groups, and patients with missing
Week-48 data were considered failures (NC = F). RESULTS: A
total of 116 of 141 (82%) ETV and 114 of 145 (79%) LAM
patients completed the questionnaires at baseline. Though ETV
patients demonstrated a clinically meaningful improvement in
HIS (0.03) and LAM patients did not (0.01), the difference (0.02)
was not statistically signiﬁcant (p = 0.12). ETV patients had a
trend towards better change in VAS at Week-48 (ETV = 4.13;
LAM = 0.91; mean difference estimate ETV-LAM = 2.11; p =
0.21). A larger proportion of ETV patients had improvement or
no change in all ﬁve health dimensions at Week-48. ETV treat-
ment was superior to LAM in the following dimensions: mobil-
ity; self care; pain or discomfort (94% vs. 82%, p = 0.007; 94%
vs. 85%, p = 0.03; and 90% vs. 77%, p = 0.01, respectively).
CONCLUSION: ETV therapy was associated with greater pro-
portions of patients with improvement or no change in mobil-
ity, self care, and pain or discomfort after 48-weeks of treatment.
ETV patients demonstrated a clinically meaningful improvement
in HIS, and greater improvement in VAS from baseline compared
to LAM.
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OBJECTIVES: To evaluate the impact of tegaserod 6mg b.i.d.
on the quality of life (QoL) of men and women with IBS-C, as
deﬁned by Rome II criteria. METHODS: A multicenter, open-
label, prospective, single-cohort study was conducted in Spain.
Patients entered a one-month, treatment-free, baseline period fol-
lowed by three months’ treatment with tegaserod 6mg b.i.d. and
subsequently, a one-month withdrawal period (no treatment).
QoL was assessed at the end of baseline, treatment and with-
drawal periods using the IBS-QOL; a validated modiﬁed disease-
speciﬁc instrument and the SF-36; a validated generic instrument.
Patients recorded their level of IBS symptom relief in a weekly
diary. Patients were considered responders (R) if ≥two-weeks’
satisfactory relief of global IBS-C symptoms was experienced
